NONMEM Users Network Archive

Hosted by Cognigen

RE: NONMEM 7 Update

From: Bill Bachman <bachmanw>
Date: Thu, 2 Jul 2009 09:04:12 -0400

ICON Development Solutions has made a considerable financial investment in
the major recoding of NONMEM done for version 7. As a commercial entity, it
believes it should protect the intellectual property via encryption while
still allowing the user to make minor adjustments to the installation.





From: owner-nmusers
Behalf Of Eleveld, DJ
Sent: Thursday, July 02, 2009 6:11 AM
To: Ludden, Thomas; nmusers
Subject: RE: [NMusers] NONMEM 7 Update


Can anyone explain what advantages encryted source code might have?


For me at least, the NONMEM source code is already functionally encrypted
because of my poor understanding of Fortran. But it is unclear to me what
problem encryted source code actually solves. Can anyone enlighten me?


Douglas Eleveld



From: owner-nmusers
Sent: Wed 01/07/2009 9:21 PM
To: nmusers
Subject: [NMusers] NONMEM 7 Update

Dear All:


This is just a brief update regarding the availability of NONMEM 7. We had
hoped to begin distribution of this new version at this time. However,
there are some final code changes to be made followed by thorough testing.
We hope to be able to begin distribution in early August.


Please be certain that the contact information that we have on file for your
license(s) is up to date. This is the person to whom NONMEM 7 will be sent
. Please send any updates regarding the correct contact person to


Please note that NONMEM 7 will have a licensing system. More details will
be provided as we approach the release date.


Our experience with distributing binary code to the beta testers was very
mixed. Some testers had no problems; others had considerable difficulty
with achieving a successful installation. We are now considering the
distribution of NONMEM 7, for the most part, as encrypted source code. An
installation program will be included. The SIZES file and several other
resource files will be left unencrypted so that the user can make desired
changes prior to compilation as was possible with previous versions. This
change in our method of distribution will require that a revised licensing
agreement be executed.




Bob Bauer

Vice-President, Pharmacometrics


Alison Boeckmann



Bill Bachman

Director, Pharmacometrics R&D


Tom Ludden

Vice-President, Pharmacometrics R&D

ICON Development Solutions

Tel: + 1 410 696 3040
Mob: + 1 410 258 2411
Fax: + 1 410 480 0776
Email: thomas.ludden


ICON plc made the following annotations.
This e-mail transmission may contain confidential or legally privileged
that is intended only for the individual or entity named in the e-mail
address. If you
are not the intended recipient, you are hereby notified that any disclosure,
distribution, or reliance upon the contents of this e-mail is strictly
prohibited. If
you have received this e-mail transmission in error, please reply to the
sender, so that
ICON plc can arrange for proper delivery, and then please delete the
Thank You,
ICON plc
South County Business Park
Dublin 18
Registered number: 145835

De inhoud van dit bericht is vertrouwelijk en alleen bestemd voor de
geadresseerde(n). Anderen dan de geadresseerde(n) mogen geen gebruik maken
van dit bericht, het niet openbaar maken of op enige wijze verspreiden of
vermenigvuldigen. Het UMCG kan niet aansprakelijk gesteld worden voor een
incomplete aankomst of vertraging van dit verzonden bericht.

The contents of this message are confidential and only intended for the eyes
of the addressee(s). Others than the addressee(s) are not allowed to use
this message, to make it public or to distribute or multiply this message in
any way. The UMCG cannot be held responsible for incomplete reception or
delay of this transferred message.


No viruses found in this incoming message
Scanned by iolo AntiVirus <>

No viruses found in this outgoing message
Scanned by iolo AntiVirus

Received on Thu Jul 02 2009 - 09:04:12 EDT

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to:

Once subscribed, you may contribute to the discussion by emailing: